Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study

NCT05809986 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT05809986
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05809986 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Recruiting
Start date
November 27, 2023
Completion date
December 31, 2026
Enrollment
174 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing multiple sclerosis